These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 26625880)

  • 21. Pravastatin and cardiovascular risk in moderate chronic kidney disease.
    Nakamura H; Mizuno K; Ohashi Y; Yoshida T; Hirao K; Uchida Y;
    Atherosclerosis; 2009 Oct; 206(2):512-7. PubMed ID: 19423108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Uric acid and incident chronic kidney disease in dyslipidemic individuals.
    Barkas F; Elisaf M; Liberopoulos E; Kalaitzidis R; Liamis G
    Curr Med Res Opin; 2018 Jul; 34(7):1193-1199. PubMed ID: 28836857
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Type of dyslipidemia and achievement of the LDL-cholesterol goal in chronic kidney disease patients at the University Hospital.
    Sangsawang T; Sriwijitkamol A
    Vasc Health Risk Manag; 2015; 11():563-7. PubMed ID: 26604773
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relation Between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study).
    Shepherd J; Breazna A; Deedwania PC; LaRosa JC; Wenger NK; Messig M; Wilson DJ;
    Am J Cardiol; 2016 Apr; 117(8):1199-205. PubMed ID: 26940556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pravastatin on cardiovascular events in people with chronic kidney disease.
    Tonelli M; Isles C; Curhan GC; Tonkin A; Pfeffer MA; Shepherd J; Sacks FM; Furberg C; Cobbe SM; Simes J; Craven T; West M
    Circulation; 2004 Sep; 110(12):1557-63. PubMed ID: 15364796
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of pitavastatin add-on therapy on chronic kidney disease with albuminuria and dyslipidemia.
    Ohsawa M; Tamura K; Wakui H; Kanaoka T; Azushima K; Uneda K; Haku S; Kobayashi R; Ohki K; Haruhara K; Kinguchi S; Toya Y; Umemura S
    Lipids Health Dis; 2015 Dec; 14():161. PubMed ID: 26645467
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The association between elevated serum uric acid level and an increased risk of renal function decline in a health checkup cohort in China.
    Cao X; Wu L; Chen Z
    Int Urol Nephrol; 2018 Mar; 50(3):517-525. PubMed ID: 29094330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.
    Nissen SE; Tuzcu EM; Schoenhagen P; Crowe T; Sasiela WJ; Tsai J; Orazem J; Magorien RD; O'Shaughnessy C; Ganz P;
    N Engl J Med; 2005 Jan; 352(1):29-38. PubMed ID: 15635110
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effect of Statin Therapy on Serum Uric Acid Levels: A Systematic Review and Meta-analysis.
    Akbari A; Razmi M; Rafiee M; Watts GF; Sahebkar A
    Curr Med Chem; 2024; 31(13):1726-1739. PubMed ID: 36748810
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of fenofibric acid on carotid intima-media thickness in patients with mixed dyslipidemia on atorvastatin therapy: randomized, placebo-controlled study (FIRST).
    Davidson MH; Rosenson RS; Maki KC; Nicholls SJ; Ballantyne CM; Mazzone T; Carlson DM; Williams LA; Kelly MT; Camp HS; Lele A; Stolzenbach JC
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1298-306. PubMed ID: 24743431
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
    Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K
    Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.
    Jones PH; Hunninghake DB; Ferdinand KC; Stein EA; Gold A; Caplan RJ; Blasetto JW;
    Clin Ther; 2004 Sep; 26(9):1388-99. PubMed ID: 15531001
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intensive lipid lowering with atorvastatin in patients with coronary artery disease, diabetes, and chronic kidney disease.
    Shepherd J; Kastelein JP; Bittner VA; Carmena R; Deedwania PC; Breazna A; Dobson S; Wilson DJ; Zuckerman AL; Wenger NK;
    Mayo Clin Proc; 2008 Aug; 83(8):870-9. PubMed ID: 18674471
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial.
    Billings FT; Hendricks PA; Schildcrout JS; Shi Y; Petracek MR; Byrne JG; Brown NJ
    JAMA; 2016 Mar; 315(9):877-88. PubMed ID: 26906014
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improved outcome after acute coronary syndromes with an intensive versus standard lipid-lowering regimen: results from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) trial.
    Rouleau J
    Am J Med; 2005 Dec; 118 Suppl 12A():28-35. PubMed ID: 16356805
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of allopurinol on the glomerular filtration rate of children with chronic kidney disease.
    Ghane Sharbaf F; Assadi F
    Pediatr Nephrol; 2018 Aug; 33(8):1405-1409. PubMed ID: 29549464
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipoprotein-associated phospholipase A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial.
    O'Donoghue M; Morrow DA; Sabatine MS; Murphy SA; McCabe CH; Cannon CP; Braunwald E
    Circulation; 2006 Apr; 113(14):1745-52. PubMed ID: 16537575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study.
    Shepherd J; Kastelein JJ; Bittner V; Deedwania P; Breazna A; Dobson S; Wilson DJ; Zuckerman A; Wenger NK;
    Clin J Am Soc Nephrol; 2007 Nov; 2(6):1131-9. PubMed ID: 17942759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.